US-based biopharmaceutical company Hoth Therapeutics Inc (NASDAQ: HOTH) on Tuesday reported positive interim data from the open-label portion of its Phase 2a clinical trial, CLEER-001, evaluating HT-001 for the treatment of pruritus associated with skin toxicities caused by Epidermal Growth Factor Receptor (EGFR) inhibitors.

HT-001 is a proprietary, non-steroidal topical formulation, being developed for the treatment of pruritus and other inflammatory skin conditions associated with targeted cancer therapies. Designed for localised application, HT-001 aims to alleviate itching and irritation without the systemic side effects of traditional treatments.

According to the company, key Interim Results (Day 1-21) showed that patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21. Rapid symptom relief was observed, with mean scores improving to 1.0 by Day 7. Some patients achieved complete resolution of pruritus within the 21-day period, and HT-001 was well tolerated, with no treatment-related serious adverse events reported.

The CLEER-001 study is ongoing, with both cohorts in effect, including the randomised, double-blind portion of the trial.